πŸ‡ΊπŸ‡Έ FDA
Patent

US 11492351

MTA-cooperative PRMT5 inhibitors

granted A61PA61P35/00

Quick answer

US patent 11492351 (MTA-cooperative PRMT5 inhibitors) held by Mirati Therapeutics, Inc. expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P35/00